Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04229277 | Fast Track Diagnosis of Skin Cancer by Advanced Imaging | completed | N/A | 41 | University Hospital Bispebjerg and FrederiksbergOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT03484923 | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma(PLATforM) | completed | Phase 2 | 196 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 18, 2024 |
| clinicaltrials |
| NCT02700971 | RATIO: Rational Approach To Immuno-Oncology(RATIO) | completed | N/A | 35 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT00341939 | Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | completed | — | 484 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03627026 | Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients(IMMUSPHINX) | completed | N/A | 78 | Institut Claudius RegaudOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02631447 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study(SECOMBIT) | completed | Phase 2 | 251 | Fondazione Melanoma OnlusOTHER | 10 | Jun 7, 2024 | clinicaltrials |
| NCT01119508 | Ipilimumab + Temozolomide in Metastatic Melanoma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT03817125 | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention(MCGRAW) | completed | Phase 1 | 14 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02847728 | Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice | completed | — | 1,189 | Bristol-Myers SquibbINDUSTRY | 14 | Jun 3, 2024 | clinicaltrials |
| NCT02821000 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | completed | Phase 1 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 30, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT02107755 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT06415929 | Etude rétrospective Monocentrique MATRIX | completed | — | 15 | Centre Hospitalier Universitaire de NiceOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | completed | Phase 1 / Phase 2 | 217 | AmgenINDUSTRY | 3 | May 14, 2024 | clinicaltrials |
| NCT03927742 | Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors | completed | N/A | 368 | University of MinnesotaOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02600143 | Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.(COLIPI) | completed | — | 123 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02600169 | Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab | completed | — | 150 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02949154 | Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients | completed | — | 65 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03520634 | PD-L1 PET Imaging in Melanoma Patients | completed | N/A | 10 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03946007 | Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors | completed | — | 134 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02760225 | Pembrolizumab-PET Imaging | completed | N/A | 18 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02970981 | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | completed | Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03711188 | A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | completed | Phase 2 | 16 | Immodulon Therapeutics LtdINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04460053 | Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.(ILP-NfL) | completed | N/A | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 24, 2024 | clinicaltrials |
| NCT01621490 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma(PD-1) | completed | Phase 1 | 170 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 23, 2024 | clinicaltrials |
| NCT01931644 | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | completed | — | 17,667 | Sanguine BiosciencesINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06163170 | A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | completed | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06369428 | Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients | completed | — | 1,795 | NovartisINDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04165967 | Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma(BaseTIL) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | completed | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | completed | Phase 1 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT04605822 | Melanoma Detection in Switzerland With VECTRA(MELVEC) | completed | — | 455 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02678741 | Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | completed | Phase 1 / Phase 2 | 26 | Elios Therapeutics, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00342797 | Retinoblastoma Biomarker Study | completed | — | 2,136 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03246412 | Nevus Doctor Clinical Decision Support for GPs | completed | N/A | 35 | University Hospital of North NorwayOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02527304 | Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery | completed | N/A | 24 | Albert Einstein College of MedicineOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02159066 | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma(LOGIC-2) | completed | Phase 2 | 158 | PfizerINDUSTRY | 9 | Mar 5, 2024 | clinicaltrials |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019448 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019890 | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 0 | Mar 4, 2024 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00020475 | Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 20, 2024source: clinicaltrials